Dynacure

@dynacure

Dynacure develops new treatments for serious orphan disorders, such as Centronuclear Myopathies.

Strasbourg, France
dynacure.com
Vrijeme pridruživanja: rujan 2017.
36 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @dynacure

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @dynacure

  1. 28. sij

    One of the symptoms of is extreme muscle weakness. Our approach hopes to make headway:

    3 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
    Poništi
  2. 22. sij

    Dynacure's CEO will participate in a panel discussion at Santé regarding ‘international financing of biotech companies’. Stéphane has over 20 years experience working for growing biotech companies that combat . More:

    2 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
    Poništi
  3. 21. sij

    We are proud to have been selected for ! This program supports companies to stimulate growth and create opportunities in France. Learn more:

    4 proslijeđena tweeta 15 korisnika označava da im se sviđa
    Poništi
  4. 20. sij

    Abnormal protein production can lead to human diseases. Antisense technology aims to stop production of these proteins. Learn more:

    3 proslijeđena tweeta 3 korisnika označavaju da im se sviđa
    Poništi
  5. 16. sij

    At Dynacure, we focus on developing new treatments for patients affected by serious orphan disorders. Our investors have made this research possible. Learn More:

    1 proslijeđeni tweet 4 korisnika označavaju da im se sviđa
    Poništi
  6. 15. sij

    We are addressing problems that have been overlooked for too long. Learn More:

    2 proslijeđena tweeta 6 korisnika označava da im se sviđa
    Poništi
  7. 14. sij

    At Dynacure, our goal is to advance a disease-modifying therapy for patients suffering from Centronuclear Myopathies (CNM), a rare group of genetic muscular disorders. Learn More:

    3 proslijeđena tweeta 7 korisnika označava da im se sviđa
    Poništi
  8. 13. sij

    We're excited to meet up with some of the greatest minds in biotech at this year's JP Morgan Healthcare Conference.

    2 proslijeđena tweeta 6 korisnika označava da im se sviđa
    Poništi
  9. 1. sij

    Happy New Year from the Dynacure team! We look forward to another year working to help patients with centronuclear myopathies!

    7 korisnika označava da im se sviđa
    Poništi
  10. 27. pro 2019.

    Unite-CNM is a European multicenter, ascending dose study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DYN101 in patients w/ XLCNM or ADCNM

    1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
    Poništi
  11. 23. pro 2019.

    The relationship between the -implicated genes in muscle is not well understood, but Dynacure co-founders Jocelyn Laporte and Belinda Cowling have demonstrated that dynamin 2 is overexpressed in X-linked

    2 proslijeđena tweeta 9 korisnika označava da im se sviđa
    Poništi
  12. 19. pro 2019.

    "With antisense, we believe there is an opportunity to reimagine the treatment of rare muscle-related disorders where no viable therapy exists." - Stephane van Rooijen (M.D. MBA), Dynacure CEO

    4 proslijeđena tweeta 8 korisnika označava da im se sviđa
    Poništi
  13. 17. pro 2019.

    Did you know? Centronuclear Myopathies are rare and affect between 4,000 and 5,000 patients in the EU, US, Japan and Australia .

    1 proslijeđeni tweet 4 korisnika označavaju da im se sviđa
    Poništi
  14. 12. pro 2019.

    New video: Dynacure bio-engineer Suzie Buono presents research into using the Aurora muscle force machine to phenotype MTM1 and DNM2 mice models, in response to ASO therapy:

    4 proslijeđena tweeta 8 korisnika označava da im se sviđa
    Poništi
  15. 10. pro 2019.

    ICYMI: Belinda Cowling receives Irène Joliot-Curie Prize for Women in Business and Technology:

    1 reply 1 proslijeđeni tweet 13 korisnika označava da im se sviđa
    Poništi
  16. 5. pro 2019.

    Dynacure's investors are advancing our research into orphan and rare diseases. Learn more:

    3 proslijeđena tweeta 8 korisnika označava da im se sviđa
    Poništi
  17. 29. stu 2019.

    Meet Morice - this 2-year-old presents the classic X-linked form of . Learn how his parents are fighting for their son:

    5 proslijeđenih tweetova 5 korisnika označava da im se sviđa
    Poništi
  18. 27. stu 2019.

    Dynacure’s chief scientific officer, Dr. Belinda Cowling, receives Irène Joliot-Curie Prize for Women in Business and Technology:

    8 proslijeđenih tweetova 15 korisnika označava da im se sviđa
    Poništi
  19. 26. stu 2019.

    We want to help patients of all ages. Our team is working to treat myopathies, a group of rare diseases that affect children and young adults:

    5 proslijeđenih tweetova 12 korisnika označava da im se sviđa
    Poništi
  20. 25. stu 2019.

    Dynacure recently presented new preclinical results on muscle targeting with oligonucleotides. Learn more and view our poster:

    3 proslijeđena tweeta 6 korisnika označava da im se sviđa
    Poništi

@dynacure još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·